Published Date: 08 Mar 2023
Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.
Read Full NewsResearchers compare enzalutamide vs abiraterone in the metastatic castration-sensitive prostate cancer setting.
A new study assesses breast and ovarian cancer risk in women who carry a BRCA variant of uncertain significance or have a noninformative negative result.
1.
Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit
2.
Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?
3.
Adopted cancer cells and the effects of their presence.
4.
A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.
5.
Words matter to people living with cancer. Here's how verbal microaggressions affect their mental state
1.
Next-Gen Cancer Therapies: Radiopharmaceuticals, Immuno-Oncology, and Biologic Breakthroughs
2.
Colon cancer: Risk factors, warning signs and treatment options
3.
Quality of Life Through Functional Reintegration After Organ-Conserving Cancer Care
4.
Quality of Life Following Functional Hematopoietic Recovery
5.
Clinical Pharmacology of Erythropoiesis-Stimulating Pathway Modulators
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
2.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation